Lexaria Releases Annual Letter from the CEO

Core Insights - Lexaria Bioscience Corp. has made significant advancements in oral drug delivery technology, particularly in the GLP-1 sector, utilizing its proprietary DehydraTECH™ (DHT) technology [3][11][60] - The company reported a substantial increase in the market for GLP-1 drugs, with worldwide revenues rising from $34.4 billion in 2024 to $51.9 billion in 2025, marking a 51% year-over-year growth [8] - Lexaria's DHT technology has shown promising results in reducing adverse events (AEs) associated with GLP-1 drugs, which are primarily injectable, thus presenting a significant market opportunity [12][14][58] 2025 Highlights - In 2025, Lexaria focused its resources on studying its DHT technology with the three leading GLP-1 drugs: semaglutide, tirzepatide, and liraglutide [5][6] - The company completed its first Phase 1b registrational study in Australia, achieving a gross total of $9.5 million through three equity raises [6][49] - Lexaria's DHT technology demonstrated positive results across all R&D studies conducted in 2025, including significant reductions in AEs [6][58] Market Dynamics - The GLP-1 drug market is becoming increasingly competitive, with new companies and products emerging regularly, and existing drugs expanding their indications beyond diabetes and weight loss [9] - Despite the overall market growth, the orally-delivered segment of GLP-1 drugs has seen limited revenue growth, with only 5% of total revenues from oral products in 2025 [10] Research and Development - Lexaria's studies in 2025 included Human Pilot Studies that showed DHT-processed drugs had reduced AEs compared to their injectable counterparts, with notable reductions in gastrointestinal issues [18][29] - The company plans to leverage findings from its 2025 studies to design new R&D work in 2026, focusing on improving oral GLP-1 formulations [34][36] Collaboration and Business Development - Lexaria has extended its Material Transfer Agreement (MTA) with a pharmaceutical partner to evaluate DHT technology, allowing for continued collaboration and strategic planning [41][43] - The company is actively pursuing discussions with various pharmaceutical companies for potential partnerships, not only in the GLP-1 sector but also in other therapeutic areas [46][48] Financial Overview - Lexaria raised $9.5 million in 2025, successfully capitalizing on favorable market conditions to fund its R&D activities through 2026 [49][50] - The company has sufficient funding to support its operations and marketing campaigns in 2026, despite previous stock price weaknesses [55][56] Future Outlook - Lexaria aims to develop the world's first oral version of liraglutide using DHT and is exploring additional R&D opportunities outside the GLP-1 sector [63][40] - The company is committed to advancing its DHT technology and believes it is closer to a commercial breakthrough than ever before [60][61]